

Table 2. Demographic and clinical follow-up data of patients

N/G	A/L	TM	FM	OT(min)	FU(m)	CG	VAS score		MSTS score		Rec	Reo	Com
							pre	po	3m-po	2y-po			
1/F ¹	30/F ²	SR	/	210	108	III	5	1	20	26	N	Y	PL
2/F	25/T	SR	/	185	104	II	5	2	18	24	Y	Y	N
3/F	49/F	SR	/	134	101	III	5	2	18	D	Y	Y	N
4/M	49/T	SR	/	178	101	III	5	1	19	26	N	N	N
5/F	18/F	SR	/	184	76	III	3	2	14	20	N	N	N
6/M	51/F	SR	/	210	71	III	5	3	20	25	N	N	N
7/M	33/T	SR	/	190	72	III	3	1	20	23	N	Y	PL
8/M	33/F	SR	/	140	68	III	3	1	20	26	N	N	N
9/M	33/F	SR	/	165	67	III	2	1	19	24	N	N	N
10/M	20/T	SR	/	300	60	III	3	1	18	24	N	N	N
11/F	70/F	SR	/	175	49	III	3	2	17	22	N	N	N
12/M	57/F	SR	/	170	49	II	5	3	20	24	N	N	N
13/F	34/F	SR	/	125	48	II	3	1	20	24	N	N	N
14/F	16/T	SR	/	125	48	III	3	1	18	26	N	N	N
15/M	53/T	SR	/	195	44	III	3	1	18	24	N	N	N
16/F	59/T	SR	/	150	46	III	5	2	19	25	N	N	N
17/M	16/F	SR	/	115	45	II	3	1	19	25	N	N	N
18/M	47/H	SR	/	195	43	II	5	3	20	22	N	N	N
19/F	21/T	SR	/	180	43	III	3	1	20	25	N	N	N
20/M	75/F	SR	/	160	42	II	3	2	20	26	N	N	N
21/F	52/H	SR	/	120	42	III	5	3	15	20	Y	Y	N
22/M	24/T	SR	/	290	39	III	3	1	20	26	N	N	N
23/F	45/F	SR	/	175	39	III	5	1	19	24	N	Y	PL
24/M	33/F	SR	/	150	38	III	5	3	20	25	N	N	N
25/M	27/F	SR	/	110	36	II	5	3	17	25	N	N	N
26/F	41/T	SR	/	195	35	II	3	1	18	23	N	N	N
27/M	35/F	SR	/	165	33	III	5	2	19	24	N	N	N
28/M	32/T	SR	/	175	32	II	3	1	19	25	N	N	N
29/F	43/T	SR	/	190	31	III	3	1	20	25	N	N	N
30/F	37/F	SR	/	170	31	III	3	2	18	24	N	N	N
31/F	37/T	TC	BC	95	104	II	5	2	19	27	N	N	N
32/F	55/F	TC	BG	115	105	II	3	1	20	27	N	N	N
33/M	25/F	TC	BC	100	98	III	3	1	20	D	Y	Y	N
34/M	26/T	TC	BG	120	91	II	3	1	20	27	N	N	N
35/F	42/T	TC	BC	99	85	II	2	0	23	26	N	N	N
36/F	33/F	TC	BG	123	77	II	3	1	21	27	N	N	N
37/F	16/F	TC	BG	130	76	II	3	1	20	27	Y	Y	N
38/M	29/F	TC	BC	90	74	II	5	3	18	27	N	N	N
39/M	24/T	TC	BC	133	71	III	3	1	24	27	N	N	N
40/M	23/F	TC	BG	80	71	II	3	1	24	27	N	N	N
41/F	19/F	TC	BC	115	70	III	3	1	18	27	Y	Y	N
42/M	28/T	TC	BC	170	70	II	5	3	19	27	N	N	N
43/M	28/T	TC	BC	170	69	III	3	1	19	25	N	N	N
44/F	30/F	TC	BG	220	69	II	3	2	18	25	N	N	N
45/F	28/F	TC	BC	175	66	III	3	2	18	27	N	N	N
46/F	17/F	TC	BG	110	63	III	3	2	20	27	N	N	N
47/M	47/T	TC	BC	155	63	III	5	3	20	27	N	N	N
48/M	33/F	TC	BC	120	62	II	3	2	19	25	N	N	N
49/M	21/F	TC	BG	150	60	II	5	3	19	27	N	N	N
50/M	30/F	TC	BC	110	59	II	3	1	19	27	N	N	N
51/M	23/F	TC	BG	110	56	II	5	3	19	26	N	N	N
52/F	26/F	TC	BC	140	56	III	5	3	21	27	N	N	N
53/M	32/F	TC	BC	155	54	III	3	1	21	26	N	N	N
54/M	38/T	TC	BC	140	54	III	3	2	18	27	N	N	N
55/M	27/F	TC	BG	55	53	III	5	3	19	26	N	N	N
56/M	19/T	TC	BG	120	51	II	3	2	18	26	N	N	N
57/F	38/F	TC	BC	110	48	III	2	1	19	26	N	N	N
58/M	28/T	TC	BG	130	47	III	3	1	21	26	N	N	N
59/M	46/F	TC	BG	115	46	III	3	1	21	26	N	N	N
60/M	42/F	TC	BC	180	44	II	5	3	18	26	N	N	N
61/M	25/T	TC	BG	170	44	III	1	0	19	26	N	N	N
62/M	13/T	TC	BG	45	44	II	2	1	21	26	N	N	IN
63/F	57/F	TC	BC	150	43	III	3	2	18	26	N	N	N
64/F	39/T	TC	BC	130	42	II	3	2	19	25	N	N	N
65/M	64/F	TC	BC	210	39	III	3	1	21	26	N	N	N
66/M	68/T	TC	BC	200	38	III	3	1	19	26	N	N	N
67/F	36/H	TC	BG	150	35	III	3	1	20	26	N	N	N
68/M	45/T	TC	BC	180	33	II	3	1	21	26	N	N	N
69/F	36/T	TC	BC	170	32	II	3	1	19	26	N	N	N
70/M	24/F	TC	BG+BC	155	31	II	5	3	20	26	N	N	N
71/F	41/H	TC	BG+BC	170	31	III	2	0	21	26	N	N	N

N/G:number/gender; A/L:age/location; TM:therapeutic modalities; FM:filling materials; OT(min):operating time; FU(m):follow-up(month); CG:Campanacci grade; VAS:Visual Analogue Score; pre:pre-operation; po:post-operation; MSTS: musculoskeletal tumor society;3m-po: three months post-operation; 2y-po: two years post-operation; Rec:recurrence; Reo:reoperation; Com:complications; F1:female; M:male; F2:femur; T:tibia; H:humerus; SR:segmental resection; TC:triple clear; BC:bone cement; BG:bone graft; PL:prosthesis loosening; IN:infection